Thymic/immune, gut-barrier and longevity peptides for resilience and healthspan.
Immune, Gut & Longevity covers the thymic and immune peptides, gut-barrier compounds, and the longevity and healthspan peptides — immune support, IBD and leaky-gut, inflammaging and cellular aging. It includes peptides with genuine international clinical use (thymosin alpha-1) alongside replication-caveated bioregulator and telomere claims, which we grade carefully.
Epitalon, MOTS-c, humanin and FOXO4-DRI are marketed as telomere-lengthening, anti-aging peptides. We grade the real evidence — replicated cell-culture data, animal healthspan signals, and the total absence of a qualifying human anti-aging trial.
An evidence-first ranking of the peptides studied for rheumatoid and autoimmune arthritis — thymosin alpha-1, BPC-157, ARA-290 and KPV — separating real human data from preclinical promise, and flagging the immune-flare risk in a joint-destroying disease.
Immune, Gut & LongevityAn evidence-first ranking of the peptides studied for the intestinal barrier — teduglutide, larazotide acetate, BPC-157 and KPV — separating one Grade-A drug for a different condition from failed, abandoned or preclinical-only 'leaky gut' claims.
Immune, Gut & LongevityAn evidence-first ranking of the peptides studied for inflammaging and chronic low-grade inflammation of aging — thymosin alpha-1, ARA-290, thymalin, BPC-157 and KPV — separating real human trials from preclinical promise, and flagging the bidirectional immune risk.
Immune, Gut & LongevityAn evidence-first ranking of the peptides studied for inflammatory bowel disease — BPC-157, KPV, thymosin alpha-1 and larazotide acetate — separating decades of rodent colitis data from the near-total absence of human IBD trials.
Immune, Gut & LongevityAn evidence-first ranking of the peptides studied for IBS — the FDA-approved GC-C agonists linaclotide and plecanatide, plus larazotide, BPC-157 and KPV — separating real human trials from preclinical promise and marketing hype.
Immune, Gut & LongevityAn evidence-first ranking of the peptides studied for immune support and function — thymosin alpha-1, thymalin, LL-37 and thymogen — separating a genuine Grade A human-trial candidate from single-school and preclinical claims.
Immune, Gut & LongevityA clinical, evidence-first review of the thymic peptides marketed for recurrent infections — thymosin alpha-1, thymalin, thymulin and thymogen. The honest headline: no peptide has an RCT showing it prevents everyday colds.
Immune, Gut & LongevityA clinical, evidence-graded review of the five peptides marketed for cardiovascular and heart health — elamipretide, angiotensin-(1-7), thymosin β4, TB-500 and BPC-157 — separating real human trials from preclinical and marketing claims.
Immune, Gut & LongevityAn evidence-first ranking of the peptides studied for autoimmune modulation — larazotide, thymosin alpha-1, ARA-290 and KPV — separating real human trials from preclinical promise, and flagging the bidirectional immune risk.
Immune, Gut & LongevityAn evidence-first ranking of the peptides most studied for aging and healthspan — elamipretide, GHK-Cu, thymalin, epitalon and MOTS-c — separating real human data from rodent and in-vitro hype.
Thymosin alpha-1 (thymalfasin, Zadaxin) is the standout: it is approved in many countries for chronic hepatitis B and C and has human trials in sepsis, cancer-adjuvant and infection settings. It has a real immunomodulatory mechanism and a substantial human evidence base, though it is not FDA-approved in the US and is under compounding review. We grade its better-supported indications to their human-trial level and distinguish them from thinner claims.
No peptide has been shown to extend human lifespan in controlled trials. Longevity peptides such as epitalon rest largely on Russian (Khavinson) human studies with limited Western replication, plus telomerase and pineal-regulation claims whose replication status is uncertain. Mitochondrial-derived peptides like MOTS-c and humanin are mostly preclinical or observational. We grade these claims conservatively (often C or D) and flag source-quality and replication concerns prominently.
The evidence is preclinical or weak. BPC-157, the most cited gut-healing peptide, has extensive animal data for ulcers and colitis but no completed human trials; KPV and others are similarly early-stage. We present the mechanistic rationale and the preclinical findings, grade them C, and are explicit that "leaky gut" and IBD are clinical conditions that should be managed with a licensed clinician, not a research-chemical peptide.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.
